Antipsychotic Effects of Oxytocin

• Status: Terminated
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with antipsychotic medication.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine; University of California, San Diego
• Collaborators: National Institute of Mental Health (NIMH); University of California, San Diego
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Adult men or women, 21 years of age or older.

• Meet DSM-IV criteria for Schizophrenia.

• Women of childbearing potential must test negative for pregnancy at the time of enrollment based on urine pregnancy test and agree to use a reliable method of birth control during the study.

• Must be on a therapeutic dose of an atypical antipsychotic medication (examples but not limited to Clozapine Olanzapine, Risperidone, Ziprasidone, Aripiprazole, Seroquel) with no major dose changes for at least 4 weeks.

• A minimum PANSS total score of 55 at screening and baseline and a score of at least 4 (moderate) on the subscale of the PANSS (suspiciousness/persecution) at screening.

• Have a Clinical Global Impressions-Severity (CGI-S) scale score of at least 4 (moderately ill) at baseline.

• Must be able to communicate effectively with the investigator and study coordinator and have the ability to provide informed consent.

• Must be able to use nasal spray.

• Must demonstrate an acceptable degree of compliance with medication and procedures in the opinion of the investigator.

Exclusion Criteria:

• Are pregnant or are breastfeeding (negative pregnancy test at screening).

• A urine drug screen performed at screening must not show evidence of recent use of drugs of abuse.

• Any active medical condition that in the opinion of the investigator will interfere with the objectives of the study.

• Are unsuitable in any way to participate in this study, in the opinion of the investigator.

• Another current DSM-IV diagnosis other than Schizophrenia.

Permitted:

• Subjects on one SSRI, and/or sleep medication (diphenhydramine, zolpidem, zaleplon, or diazepam), at a reasonable dose, as judged by the investigator, is permitted in this study. Minor adjustments in sleep medication are acceptable. Patients will be asked to notify the study doctor of any changes to sleep aids.